Assessment of the renal function
In the present study, the eGFR calculated by 194 x
age-0.287 x serum creatinine-1.094(x
0.739 for women)14 was evaluated as the renal function
in all the subjects. In the ablation group, the eGFR within one month
before the CA was defined as the baseline eGFR and evaluated three
months and 12 months after the ablation. Among the patients who had
recurrence of AF and underwent repeat ablation sessions, the
post-ablation eGFR was evaluated after the last session. In the control
group, the baseline eGFR was evaluated at the date of the AF
documentation and evaluated three months and 12 months thereafter. Among
the patients whose AF onset was unknown, the baseline eGFR was evaluated
on the day the follow-up was started at the study institute. The ΔeGFR
was defined as the change in the eGFR between baseline and 12 months and
compared between the two groups. The difference in the ΔeGFR between the
patients with paroxysmal AF (PAF) and non-PAF in the ablation group was
also evaluated. Specifically, patients with an eGFR ≥90 mL/min/1.73
m2 were classified as a CKD stage G1, an eGFR of 60-89
mL/min/1.73 m2 as a CKD stage G2, an eGFR of 45-59
mL/min/1.73m2 as a CKD stage G3a, an eGFR of 30-44
mL/min/1.73 m2 as a CKD stage G3b, an eGFR of 15-29
mL/min/1.73 m2 as a CKD stage 4, and an eGFR
<15 mL/min/1.73 m2 as a CKD stage G5.